Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02985957 · ClinicalTrials.gov registry record · Phase 2
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
A Phase 2 study of Prostate Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 351
- Enrollment target
- 20
- Study locations
NCT02985957 is a Phase 2 study of Prostate Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 351 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02985957, a Phase 2 study of Prostate Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 351 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
Conditions Studied
Interventions
- DRUG Prednisone
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG Cabazitaxel
Study Locations (20)
New York
- Local Institution - 0078 - Albany
- Local Institution - 0065 - Lake Success
- Local Institution - 0001 - New York
New South Wales
- Local Institution - 0027 - Gosford
- Local Institution - 0059 - Wahroonga
- Local Institution - 0029 - Westmead
Pennsylvania
- Local Institution - 0047 - Allentown
- Local Institution - 0010 - Philadelphia
Texas
- Local Institution - 0079 - Austin
- Local Institution - 0002 - Houston
Queensland
- Local Institution - 0028 - Southport
- Local Institution - 0043 - Woolloongabba
Arizona
- Local Institution - 0074 - Tucson
Georgia
- Local Institution - 0046 - Marietta
Illinois
- Local Institution - 0011 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2017-03-26 |
| Est. Completion | 2025-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02985957
The ClinicalTrials.gov registry entry for NCT02985957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (42% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Prednisone is the first listed.
NCT02985957 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, New South Wales, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02985957 about?
NCT02985957 is a clinical study titled "A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)". The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
What is the current status of trial NCT02985957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 351 participants. The study started on 2017-03-26. Estimated completion is 2025-01-07.
What conditions does trial NCT02985957 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02985957?
The interventions under investigation include: Prednisone (DRUG), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT02985957?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02985957 being conducted?
This trial has 20 study locations across Arizona, Georgia, Illinois, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.